Literature DB >> 20137623

[Molecular cloning of a novel gene, C5orf21 gene and its roles in diabetic macroangiopathy].

Lian-xi Li1, Zheng Tao, Xue-hong Dong, Wen-chang Liang, Zhi-hong Yang, Bo Mou, Yu-qian Bao, Chen Wang, Wei-ping Jia, Ren-ming Hu.   

Abstract

OBJECTIVE: To clone a novel diabetic angiopathy related protein gene-C5orf21 and study its roles in diabetic macroangiopathy.
METHODS: The open reading frame (ORF) of C5orf21 gene was cloned into vector from human aortic tissues by a RT-PCR-based approach and identified by enzyme-cutting and sequencing. The structure and function of C5orf21 gene and protein were further analyzed by bioinformatics technology. The mRNA expression of C5orf21 gene in human tissues and in vascular cells was analyzed by RT-PCR. RT-PCR was used to observe the effect of high glucose, low-density lipoprotein (LDL) and free fatty acid (FFA) upon the expression of C5orf21 gene in macrophages.
RESULTS: C5orf21 gene was successfully inserted into pDrive vector and identified for the first time at the level of mRNA. There are five C5orf21 gene splice variants in human aortic tissue and their length of ORF are 1251, 1113, 894, 810 and 810 bp respectively. Two kinds of splice variants have yet to be included in GenBank database. Two kinds of splice variants have the same ORF and their differences are mainly in the bases in the 5' untranslated region. Bioinformatics analysis found that C5orf21 gene was located in chromosome 5q15 and C5orf21 protein contained Arb2 domain associated with histone H3 lysine 9 methylation. C5orf21 gene was normally expressed in many tissues. Fat and aortic tissues had the highest expression. The expression of C5orf21 gene could be detected in human aortic endothelial cell, aortic smooth muscle cell and macrophages. High glucose, LDL and FFA (esp.high glucose) up-regulated the expression of C5orf21 gene in macrophage.
CONCLUSION: C5orf21 gene contains five splice variants and it is identified for the first time at the level of mRNA. The changes of C5orf21 gene expression are correlated with diabetic macroangiopathy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20137623

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Za Zhi        ISSN: 0376-2491


  7 in total

1.  FAM172A is a tumor suppressor in colorectal carcinoma.

Authors:  Chunhui Cui; Lili Ye; Zonghai Huang; Shuxin Huang; Hao Liu; Jinlong Yu
Journal:  Tumour Biol       Date:  2015-12-04

2.  Expression of family with sequence similarity 172 member A and nucleotide-binding protein 1 is associated with the poor prognosis of colorectal carcinoma.

Authors:  Wenjun Liu; Shuang Wang; Kai Qian; Jinqian Zhang; Zhi Zhang; Hao Liu
Journal:  Oncol Lett       Date:  2017-07-15       Impact factor: 2.967

3.  Effect of Repaglinide on Blood Glucose, Endothelial Function, Lipid Metabolism, and Inflammatory Reaction in a Rat Model of Atherosclerosis.

Authors:  Jie Chang; Bing Liu; Yan-Xia Cheng; Jin-Guang Zhang; Shuo Tao; Hong-Ling Yan
Journal:  Dose Response       Date:  2020-04-13       Impact factor: 2.658

4.  The Effect of Protein FAM172A on Proliferation in HepG2 Cells and Investigation of the Possible Molecular Mechanism.

Authors:  Hong Zhao; Yujie Wang; Yufeng Liu; Xiaohua Hao; Hongshan Wei; Wen Xie
Journal:  Anal Cell Pathol (Amst)       Date:  2019-12-13       Impact factor: 2.916

5.  Characterization of lncRNA and mRNA profiles in rats with diabetic macroangiopathy.

Authors:  Chan Yang; Ziyan Xie; Qiangfei Yang; Min Su; Ran Yan; Xueqin Cai; Xiaoxu Fu; Hong Gao; Lian Du; Wen Zhong; Chunguang Xie
Journal:  PLoS One       Date:  2020-12-30       Impact factor: 3.240

6.  FAM172A modulates apoptosis and proliferation of colon cancer cells via STAT1 binding to its promoter.

Authors:  Kai Qian; Jinqian Zhang; Jingbo Lu; Wenjun Liu; Xingxing Yao; Qing Chen; Shun Lu; Guoan Xiang; Hao Liu
Journal:  Oncol Rep       Date:  2015-12-10       Impact factor: 3.906

7.  FAM172A affects cell proliferation and apoptosis not by targeting β-tubulin in HepG2 cells.

Authors:  Ai-Min Xu; Chuan-Jiang He; Zureguli Tuerxun; Abuduaini Anikezi
Journal:  Transl Cancer Res       Date:  2020-09       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.